Gilead hepatitis C drug patent faces European challenge

Gilead hepatitis C drug patent faces European challenge


Two international medical humanitarian organisations said on Monday they had challenged the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. Sofosbuvir, sold by the U.S. drugmaker as Sovaldi, is transforming the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres and Medecins du Monde said its high cost was a serious barrier.



from Biotech News